S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

$27.25
+0.47 (+1.76%)
(As of 03/27/2024 ET)
Today's Range
$26.99
$27.29
50-Day Range
$26.40
$32.56
52-Week Range
$22.01
$33.71
Volume
1.46 million shs
Average Volume
1.91 million shs
Market Capitalization
$4.55 billion
P/E Ratio
13.16
Dividend Yield
N/A
Price Target
$33.14

Alkermes MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
21.6% Upside
$33.14 Price Target
Short Interest
Bearish
8.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
0.53mentions of Alkermes in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$292,718 Sold Last Quarter
Proj. Earnings Growth
-7.59%
From $2.24 to $2.07 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

338th out of 939 stocks

Pharmaceutical Preparations Industry

153rd out of 422 stocks

ALKS stock logo

About Alkermes Stock (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Stock Price History

ALKS Stock News Headlines

Alkermes (NASDAQ:ALKS) Now Covered by Robert W. Baird
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Alkermes exec sells over $290k in company shares
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Short Interest in Alkermes plc (NASDAQ:ALKS) Expands By 6.5%
ALKS Factor-Based Stock Analysis
Top 3 Biotech Stocks to Consider for March Profits
UBS Downgrades Alkermes (ALKS)
ALKS Mar 2024 32.000 call
Alkermes Full Year 2023 Earnings: Beats Expectations
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/27/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,100
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$33.14
High Stock Price Target
$39.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+21.6%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$355.76 million
Pretax Margin
25.34%

Debt

Sales & Book Value

Annual Sales
$1.66 billion
Cash Flow
$2.27 per share
Book Value
$7.21 per share

Miscellaneous

Free Float
159,123,000
Market Cap
$4.55 billion
Optionable
Optionable
Beta
0.57

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives


ALKS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price target for 2024?

9 analysts have issued 1 year price objectives for Alkermes' stock. Their ALKS share price targets range from $25.00 to $39.00. On average, they predict the company's stock price to reach $33.14 in the next year. This suggests a possible upside of 21.6% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2024?

Alkermes' stock was trading at $27.74 at the beginning of the year. Since then, ALKS stock has decreased by 1.8% and is now trading at $27.25.
View the best growth stocks for 2024 here
.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest in March. As of March 15th, there was short interest totaling 14,080,000 shares, an increase of 8.1% from the February 29th total of 13,020,000 shares. Based on an average trading volume of 1,840,000 shares, the days-to-cover ratio is currently 7.7 days.
View Alkermes' Short Interest
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings results on Thursday, February, 15th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.29. The firm earned $377.50 million during the quarter, compared to analysts' expectations of $362.78 million. Alkermes had a trailing twelve-month return on equity of 16.10% and a net margin of 21.39%. The firm's revenue for the quarter was up 23.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.02) EPS.

How will Alkermes' stock buyback program work?

Alkermes announced that its Board of Directors has initiated a stock buyback program on Thursday, February 15th 2024, which allows the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 8.2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (12.56%), Vanguard Group Inc. (12.54%), Wellington Management Group LLP (9.12%), Hardman Johnston Global Advisors LLC (3.28%), RTW Investments LP (2.34%) and Primecap Management Co. CA (2.14%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
This page (NASDAQ:ALKS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners